295: Humira’s legacy, CEO symbolism, and genomic surgery
First, former Alnylam Pharmaceuticals CEO John Maraganore and STAT’s Matthew Herper join us to discuss the legacy of AbbVie chief executive Richard Gonzalez, who announced his retirement this week. Th...
22 Feb 202434min
294: Pharma goes to Washington, Alnylam's future, & Gilead's dealmaking
The pharmaceutical industry, in court and in Congress, is working to water down legislation that will let Medicare negotiate certain drug prices. STAT Washington correspondent Rachel Cohrs joins us to...
15 Feb 202430min
293: AI in medicine, detangling hype, and Icelandic DNA
It's our all-AI episode. First, STAT’s Casey Ross joins us to explain his reporting on how researchers and pharmaceutical firms are using the technology to find new drug targets, design therapies, and...
8 Feb 202432min
292: Vertex's polarizing data, Aduhelm's adieu, & an FDA icon
We explain the debate over Vertex Pharmaceuticals' novel pain drug, whose success in clinical trials comes with a sizable caveat. We also talk about the latest news in the life sciences, including an ...
1 Feb 202435min
291: The plight of the VC, Gilead's latest setback, & more M&A
We discuss how biotech's downturn has made life difficult not just for startups but also the VCs they rely on for much-needed funding. We also take a look at Gilead Sciences' struggle to turn itself i...
25 Jan 202431min
290: Biotech layoffs, slumping stocks, and a 2024 preview
Our colleague Jason Mast joins us to discuss an emerging trend in biotech: Cash-rich startups are laying off employees and tweaking their strategies amid a tough market for venture capital. We also lo...
18 Jan 202442min
289: Live! From #JPM24
Recording from the STAT co-working space outside the J.P. Morgan Healthcare Conference, we discuss how a spate of deals and some intermittent sunshine seem to have brightened the outlook for biotech a...
11 Jan 202428min
287: 2023 in review, CEO report cards, and a look at the year ahead
It's our last episode of 2023, so we look back on the biggest stories of the year, discuss the best and worst CEOs in the industry, and make some reasonably informed guesses on what 2024 has in store ...
21 Des 202327min
